Form 4: Protagonist Therapeutics Director Awarded Equity

Protagonist Therapeutics director Harold E. Selick received a grant of restricted stock units and stock options, increasing his beneficial ownership.

Summary

• Director Harold E. Selick was granted 2,695 restricted stock units (RSUs) of Protagonist Therapeutics, Inc. common stock on January 2, 2026.
• These RSUs were acquired at a price of $0 and will vest in full on January 15, 2027, contingent on his continued service to the Issuer.
• Additionally, Selick was granted stock options to purchase 3,762 shares of common stock with an exercise price of $87.18, also on January 2, 2026.
• These stock options will vest in 12 equal monthly installments following January 2, 2026, subject to his continued service.
• Following these transactions, Selick beneficially owns 46,546 shares of common stock and 3,762 stock options.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, which is generally positive for aligning interests and retaining talent, but does not contain significant new operational or financial news.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with long-term shareholder value.
• Equity awards are a common incentive for retaining key management and directors.

Negatives

• No immediate cash inflow for the director from the RSU grant (price $0) or option grant (price $0 for the grant itself, but exercise price is $87.18).
• The vesting conditions tie the director to the company for future periods, which could be seen as a commitment but also limits immediate liquidity.

Risks

• The value of the restricted stock units and stock options is subject to the future performance of Protagonist Therapeutics' stock price.
• Vesting is contingent on continued service, meaning the awards could be forfeited if the director's service terminates before vesting dates.

Future Outlook

The equity grants are structured with future vesting dates, indicating an expectation of continued service from the director and a long-term alignment with company performance.

Industry Context

Equity grants to directors and executives are a standard practice in the biotechnology and pharmaceutical industry, including companies like Protagonist Therapeutics, to attract, retain, and incentivize leadership by aligning their financial interests with long-term shareholder value and company success.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as a form of director compensation is a common practice across the biotech sector, similar to compensation structures seen at companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.
• Vesting schedules tied to continued service, such as the full vesting of RSUs on a specific future date (January 15, 2027) and monthly vesting for options, are typical mechanisms designed to promote long-term commitment and performance, consistent with industry benchmarks.
• The grant of equity at a $0 price for RSUs and an exercise price for options reflects standard incentive compensation practices, where the value realized by the director is directly linked to the company's stock price appreciation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: Standard equity compensation practices can positively influence overall employee morale and retention strategies.

Next Steps

• The 2,695 restricted stock units will vest in full on January 15, 2027, subject to continued service.
• The 3,762 stock options will vest in 12 equal monthly installments following January 2, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director, which is a standard practice for aligning management incentives with shareholder interests. It does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing fundamental analysis of Protagonist Therapeutics.

Keywords

Protagonist Therapeutics, PTGX, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Beneficial Ownership